{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:30:28Z","timestamp":1793457028334,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.msard.2025.106724","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T06:57:18Z","timestamp":1756969038000},"page":"106724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The real-world efficacy of Cladribine tablets and treatment persistence in people with highly active relapsing multiple sclerosis in Finland \u2013 A follow-up study after four years of observation"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-9631","authenticated-orcid":false,"given":"Ilkka","family":"Rauma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2854-2410","authenticated-orcid":false,"given":"Matias","family":"Viitala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6930-0229","authenticated-orcid":false,"given":"Merja","family":"Soilu-H\u00e4nninen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1293-9325","authenticated-orcid":false,"given":"Sari","family":"Atula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0104-2849","authenticated-orcid":false,"given":"Sini","family":"Laakso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3697-4961","authenticated-orcid":false,"given":"Hanna","family":"Kuusisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8674-020X","authenticated-orcid":false,"given":"Marja","family":"Niiranen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3814-371X","authenticated-orcid":false,"given":"Mervi","family":"Ryytty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8802-3703","authenticated-orcid":false,"given":"Visa","family":"Manni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.msard.2025.106724_bib0001","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2174\/1570159X21666230322140711","article-title":"Real-world effectiveness of Cladribine for patients with multiple sclerosis: a Sicilian multicentric experience (Rewind Study)","volume":"22","author":"Arena","year":"2024","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.msard.2025.106724_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103385","article-title":"Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis","volume":"57","author":"Brochet","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"14","key":"10.1016\/j.msard.2025.106724_bib0003","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1177\/13524585231205962","article-title":"Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: the CLARIFY-MS study","volume":"29","author":"Brochet","year":"2023","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2025.106724_bib0004","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00415-018-8830-y","article-title":"Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells","volume":"265","author":"Ceronie","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106724_bib0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis","volume":"29","author":"Cook","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2025.106724_bib0006","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40120-024-00603-y","article-title":"Narrative review on the use of cladribine tablets as exit therapy for stable elderly patients with Multiple sclerosis","volume":"13","author":"de Seze","year":"2024","journal-title":"Neurol. Ther."},{"issue":"4","key":"10.1016\/j.msard.2025.106724_bib0007","doi-asserted-by":"crossref","first-page":"e1187","DOI":"10.1212\/NXI.0000000000001187","volume":"9","author":"de Stefano","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106724_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103490","article-title":"Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years","volume":"58","author":"Disanto","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2025.106724_bib0010","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/13524585231161494","article-title":"Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY Extension cohort of CLASSIC-MS: an ambispective study","volume":"29","author":"Giovannoni","year":"2023","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2025.106724_bib0011","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.msard.2025.106724_bib0012","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1007\/s12325-021-01865-w","article-title":"Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets 3.5 mg\/kg for relapsing multiple sclerosis: an exploratory post hoc analysis of the CLARITY and CLARITY extension studies","volume":"38","author":"Giovannoni","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.msard.2025.106724_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.763433","article-title":"Integrated lymphopenia analysis in younger and older patients with multiple sclerosis treated with cladribine tablets","volume":"12","author":"Giovannoni","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2025.106724_bib0014","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40120-022-00339-7","article-title":"Cladribine tablets for relapsing-remitting multiple sclerosis: a clinician's review","volume":"11","author":"Giovannoni","year":"2022","journal-title":"Neurol. Ther."},{"issue":"12","key":"10.1016\/j.msard.2025.106724_bib0015","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2025.106724_bib0016","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s13311-017-0573-4","article-title":"Cladribine to treat relapsing forms of Multiple sclerosis","volume":"14","author":"Giovannoni","year":"2017","journal-title":"Neurotherapeutics."},{"issue":"Q4","key":"10.1016\/j.msard.2025.106724_bib0017","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7224\/1537-2073.2023-082","article-title":"MyMS: an interface for patient-reported outcomes for Finnish individuals with multiple sclerosis","volume":"26","author":"H\u00e4m\u00e4l\u00e4inen","year":"2024","journal-title":"Int. J. MS. Care"},{"key":"10.1016\/j.msard.2025.106724_bib0018","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2147\/CLEP.S480525","article-title":"Harmonized data quality indicators maintain data quality in long-term safety studies using multiple sclerosis registries\/data sources: experience from the CLARION study","volume":"16","author":"Hillert","year":"2024","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.msard.2025.106724_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105704","article-title":"Real-world therapy management of patients with multiple sclerosis receiving cladribine tablets beyond year 4 - results from a German cladribine cohort","volume":"88","author":"Kowarik","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2025.106724_bib0020","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/ane.13145","article-title":"Multiple sclerosis in Finland 2018-data from the national register","volume":"140","author":"Laakso","year":"2019","journal-title":"Acta Neurol. Scand."},{"issue":"3","key":"10.1016\/j.msard.2025.106724_bib0021","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1352458520921087","article-title":"Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: an MSBase registry substudy","volume":"27","author":"Lizak","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106724_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577966","article-title":"Cladribine treatment for highly active multiple sclerosis: real-world clinical outcomes for years 3 and 4","volume":"372","author":"Magalashvili","year":"2022","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106724_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123070","article-title":"Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: a real-world, single centre study considering a two-year interval from year-2 dosing","volume":"462","author":"Manni","year":"2024","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106724_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104459","article-title":"Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: systematic literature review of real-world evidence","volume":"69","author":"Oreja-Guevara","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106724_bib0026","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420922685","article-title":"Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)","volume":"13","author":"Patti","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106724_bib0027","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585211012227","article-title":"Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres","volume":"28","author":"Pfeuffer","year":"2022","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2025.106724_bib0028","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/ane.13057","article-title":"Multiple sclerosis epidemiology in Finland: regional differences and high incidence","volume":"139","author":"Pirttisalo","year":"2019","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2025.106724_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103755","article-title":"Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study","volume":"61","author":"Rauma","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2025.106724_bib0030","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/WNF.0000000000000598","article-title":"Real-world effectiveness and safety of cladribine in Multiple sclerosis: longitudinal data from the nationwide registry in Argentina","volume":"47","author":"Rojas","year":"2024","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.msard.2025.106724_bib0031","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241233858","article-title":"Cladribine tablets after treatment with natalizumab (CLADRINA) - rationale and design","volume":"17","author":"Sguigna","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106724_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104491","article-title":"Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: a Danish nationwide study","volume":"70","author":"Sorensen","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106724_bib0033","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419836913","article-title":"Pulsed immune reconstitution therapy in multiple sclerosis","volume":"12","author":"Sorensen","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"4","key":"10.1016\/j.msard.2025.106724_bib0034","doi-asserted-by":"crossref","first-page":"371","DOI":"10.5603\/PJNNS.a2023.0050","article-title":"Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic","volume":"57","author":"St\u0119pie\u0144","year":"2023","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.msard.2025.106724_bib0035","series-title":"National Institutes of Health, National Cancer Institute","year":"2017"},{"issue":"7","key":"10.1016\/j.msard.2025.106724_bib0036","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1007\/s00415-023-11700-7","volume":"270","author":"Zanetta","year":"2023","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106724_bib0037","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/13524585221111677","article-title":"Prediction of relapse activity when switching to cladribine for multiple sclerosis","volume":"29","author":"Zhong","year":"2023","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:15:39Z","timestamp":1774998939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825004663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":35,"alternative-id":["S2211034825004663"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106724","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The real-world efficacy of Cladribine tablets and treatment persistence in people with highly active relapsing multiple sclerosis in Finland \u2013 A follow-up study after four years of observation","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106724","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106724"}}